미세잔존질환(MRD) 검사 시장 규모, 점유율, 동향 분석 보고서 : 기술별, 암 유형별, 용도별, 지역별 및 부문별 예측(2026-2033년)

Minimal Residual Disease Testing Market Summary

The global minimal residual disease testing market size was valued at USD 2.6 billion in 2025 and is projected to grow from USD 3.0 billion in 2026 to USD 7.1 billion by 2033, at a CAGR of 13.2% from 2026 to 2033. North America dominated the market with the largest revenue share of 46.4% in 2025.

Global Minimal Residual Disease Testing Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global minimal residual testing disease market report based on cancer type, technology, end use, and region:

• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Flow Cytometry
• Polymerase Chain Reaction (PCR)
• Next Generation Sequencing (NGS)
• Others
• Cancer Outlook (Revenue, USD Million, 2021 - 2033)
• Hematological Malignancy
  • Leukemia
  • Lymphoma
• Solid Tumors
• End use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals and Specialty Clinics
• Diagnostic Laboratories
• Academic and Research Institutes
• Others
• Regional Outlook (Revenue, USD Billion, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Technology
  • 1.2.2. Cancer Type
  • 1.2.3. End use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Technology Outlook
  • 2.2.2. Test Type Outlook
  • 2.2.3. Cancer Type Outlook
  • 2.2.4. End use Outlook
  • 2.2.5. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Minimal Residual Disease Testing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. Minimal Residual Disease Testing Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. Minimal Residual Disease Testing Market: Technology Estimates & Trend Analysis

• 4.1. Technology Market Share, 2025 & 2033
• 4.2. Segment Dashboard
• 4.3. Global Minimal Residual Disease Testing Market by Technology Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 4.4.1. Flow Cytometry
    • 4.4.1.1. Flow Cytometry market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.2. Polymerase Chain Reaction (PCR)
    • 4.4.2.1. Polymerase Chain Reaction (PCR) market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.3. Next Generation Sequencing (NGS)
    • 4.4.3.1. Next Generation Sequencing (NGS) market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.4. Others
    • 4.4.4.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Minimal Residual Disease Testing Market: Cancer Type Estimates & Trend Analysis

• 5.1. Cancer Type Market Share, 2025 & 2033
• 5.2. Segment Dashboard
• 5.3. Global Minimal Residual Disease Testing Market by Cancer Type Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 5.4.1. Hematological Malignancy
    • 5.4.1.1. Hematological Malignancy market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.1.2. Leukemia
      • 5.4.1.2.1. Leukemia market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.1.3. Lymphoma
      • 5.4.1.3.1. Lymphoma market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.4.2. Solid Tumors
    • 5.4.2.1. Solid Tumors market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Minimal Residual Disease Testing Market: End use Estimates & Trend Analysis

• 6.1. End use Market Share, 2025 & 2033
• 6.2. Segment Dashboard
• 6.3. Global Minimal Residual Disease Testing Market by End use Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 6.4.1. Hospitals and Specialty Clinics
    • 6.4.1.1. Hospitals and Specialty Clinics market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.2. Academic and Research Institutes
    • 6.4.2.1. Academic and Research Institutes market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.3. Diagnostic Laboratories
    • 6.4.3.1. Diagnostic Laboratories market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.4. Others
    • 6.4.4.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Minimal Residual Disease Testing Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2025 & 2033
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 7.5. North America
  • 7.5.1. North America: SWOT Analysis
  • 7.5.2. U.S.
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.3. Canada
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.4. Mexico
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 7.6. Europe
  • 7.6.1. Europe: SWOT Analysis
  • 7.6.2. UK
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.3. Germany
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.4. France
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.5. Italy
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.6. Spain
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Regulatory framework
    • 7.6.6.3. Competitive scenario
    • 7.6.6.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.7. Norway
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Regulatory framework
    • 7.6.7.3. Competitive scenario
    • 7.6.7.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.8. Sweden
    • 7.6.8.1. Key country dynamics
    • 7.6.8.2. Regulatory framework
    • 7.6.8.3. Competitive scenario
    • 7.6.8.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.9. Denmark
    • 7.6.9.1. Key country dynamics
    • 7.6.9.2. Regulatory framework
    • 7.6.9.3. Competitive scenario
    • 7.6.9.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Asia Pacific: SWOT Analysis
  • 7.7.2. Japan
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.3. China
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.4. India
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.5. Australia
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Regulatory framework
    • 7.7.5.3. Competitive scenario
    • 7.7.5.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.6. South Korea
    • 7.7.6.1. Key country dynamics
    • 7.7.6.2. Regulatory framework
    • 7.7.6.3. Competitive scenario
    • 7.7.6.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.7. Thailand
    • 7.7.7.1. Key country dynamics
    • 7.7.7.2. Regulatory framework
    • 7.7.7.3. Competitive scenario
    • 7.7.7.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 7.8. Latin America
  • 7.8.1. Latin America: SWOT Analysis
  • 7.8.2. Brazil
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8.3. Argentina
    • 7.8.3.1. Key country dynamics
    • 7.8.3.2. Regulatory framework
    • 7.8.3.3. Competitive scenario
    • 7.8.3.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 7.9. MEA
  • 7.9.1. MEA: SWOT Analysis
  • 7.9.2. South Africa
    • 7.9.2.1. Key country dynamics
    • 7.9.2.2. Regulatory framework
    • 7.9.2.3. Competitive scenario
    • 7.9.2.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.9.3. Saudi Arabia
    • 7.9.3.1. Key country dynamics
    • 7.9.3.2. Regulatory framework
    • 7.9.3.3. Competitive scenario
    • 7.9.3.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.9.4. UAE
    • 7.9.4.1. Key country dynamics
    • 7.9.4.2. Regulatory framework
    • 7.9.4.3. Competitive scenario
    • 7.9.4.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.9.5. Kuwait
    • 7.9.5.1. Key country dynamics
    • 7.9.5.2. Regulatory framework
    • 7.9.5.3. Competitive scenario
    • 7.9.5.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2025
  • 8.3.4. Exact Sciences Corporation.
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. GRAIL, LLC
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Veracyte, Inc.
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Natera, Inc.
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Guardant Health
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. F. Hoffmann-La Roche Ltd
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. FOUNDATION MEDICINE, INC.
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. QIAGEN
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. mdxhealth.
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. Bio-Techne.
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives